摘要
目的观察吡格列酮治疗2型糖尿病合并代谢综合征的临床疗效。方法选择68例患者随机分为研究组与对照组，各34例。两组患者均应用二甲双胍进行治疗，部分患者根据病情合用格列美脲，同时采用饮食、运动控制治疗。研究组则在上述基础治疗上加用吡格列酮30mgQd。结果研究组随访6个月时的HbA1c水平明显低于对照组（P〈0．05）HOMA—IR在随访3个月和6个月时研究组均明显低于对照组（P〈0．05）研究组HDL—c在随访3个月和6个月时均明显高于基线水平垆〈0．05）研究组DBP在随访6个月时明显低于对照组垆〈0．05）。结论吡格列酮可同时干预MS的多个指标，从而提高2型糖尿病合并代谢综合征的治疗效果。
Objective To observe the clinical effect of type 2 diabetes mellitus combined with metabolic syndrome with pioglitazone. Methods 68 cases of patients were divided randomly into study group and control group, each 34 cases. Two groups were treated with mefformin. According to the condition, some patients were treated combined with glimepiride, diet and exercise control. Study group took more pioglitazone 30mg Qd. Results At 6 months follow-up, the HbAlc level of study group was significantly lower than control group（P〈 0.05）. At 3 and 6 months follow-up, the HOMA-IR of study group was significantly lower than control group（P〈 0.05） and the HDL- c of study group was significantly higher than baseline level（P〈 0.05）. At 6 months follow-up, the DBP of study group was significantly lower than control group（P〈 0.05）. Conclusion Pioglitazone could interfere with a number of MS components at the same time to improve the treatment effect of patients with T2DM and MS.
出处
《国际医药卫生导报》
2009年第9期74-77,共4页
International Medicine and Health Guidance News
关键词
2型糖尿病
代谢综合征
吡格列酮
type 2 diabetes mellitus
metabolic syndrome
pioglitazone
